In a patient taking warfarin, when is thrombolysis appropriate and what INR threshold and reversal steps are required?

Thrombolysis in Warfarin Patients

For patients on warfarin presenting with acute ischemic stroke, IV thrombolysis is recommended when INR ≤1.7, but should NOT be performed when INR >1.7, even after reversal with prothrombin complex concentrates (PCCs). 1

INR-Based Decision Algorithm

INR ≤1.7

• Proceed with IV thrombolysis 1
• This threshold is supported by large registry data showing no significant increase in symptomatic intracranial hemorrhage (sICH) compared to non-warfarin patients when INR is maintained at or below this level 1
• The SITS European registry (45,074 patients) demonstrated that warfarin use with INR ≤1.7 (median 1.2) was not associated with increased sICH (adjusted OR 1.3,95% CI: 0.8-1.7) or worse functional outcomes 1

INR >1.7

• Do NOT perform IV thrombolysis 1
• Critically important: Reversal with PCCs does NOT make thrombolysis safe - even after normalizing INR with PCCs, thrombolysis remains contraindicated 1
• This is a common pitfall: clinicians may assume that reversing the INR makes thrombolysis acceptable, but the guidelines explicitly recommend against this approach
• The underlying coagulation factor depletion and PCC administration create an unpredictable hemostatic environment

Mechanical Thrombectomy

• Should be considered for proximal vessel occlusion regardless of INR level or whether thrombolysis was performed 1
• This is a Grade 1+ recommendation with strong agreement
• Thrombectomy carries lower bleeding risk than thrombolysis and should not be withheld based on anticoagulation status alone

Practical Implementation Steps

Before thrombolysis consideration:

1. Obtain rapid INR measurement - use point-of-care testing (POCT) if available to avoid delays 1
2. Do not delay measurement, but also do not delay imaging or other acute stroke protocols
3. If INR unavailable and patient is known to be on warfarin, assume INR may be elevated and proceed with caution

Key nuances from the evidence:

• Meta-analyses show that warfarin patients with median INR 1.1-1.5 had higher sICH rates (10.4% vs 5.4%; OR 2.5) compared to non-warfarin patients, but this did not translate to worse functional outcomes 1
• For INR >1.7, reported sICH rates range from 0-30% in small case series - this wide variability reflects the high risk and unpredictability 1
• One small case series attempted PCC reversal before thrombolysis in patients with INR >1.7, showing no hemorrhagic events in 3 days, but this approach is NOT recommended by current guidelines 1

Other Anticoagulants

Heparin products:

• Therapeutic UFH, LMWH, or fondaparinux: Do NOT perform thrombolysis 1
• No recommendation exists for protamine use prior to thrombolysis in UFH patients - insufficient evidence 1

DOACs:

• Different thresholds apply - see DOAC-specific protocols
• Dabigatran: Can proceed if concentration <50 ng/mL or after idarucizumab 5g IV 1
• Anti-Xa DOACs: Can proceed if concentration <50 ng/mL 1

Critical Caveats

• The 1.7 INR threshold is absolute - there is no gray zone for clinical judgment here
• Time is brain, but safety trumps speed: a 10-minute delay to obtain INR is justified
• Document INR value and decision-making clearly in the medical record
• Consider thrombectomy as primary reperfusion strategy in warfarin patients with INR >1.7 and large vessel occlusion